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Background: The study aims to evaluate the expression and activity of glycogen synthase kinase 3 isoforms α/β
(GSK3α/β) and to assess their oncogenic potential through a correlation with the expression of cyclin D1 and p53
in oral cancer.
Methods: The expression of total and phosphorylated GSK3α/β as well as cyclin D1 and p53 together with their
interaction were assessed in human oral cancer tissue samples, apparently normal adjacent tissues, benign tumor
samples, premalignant lesions and healthy normal tissues (total 179) using various methods, such as
immunohistochemistry, Western blot assays, immunoprecipitation and RT-PCR analysis.
Results: The expression of GSK3β was significantly higher relative to GSK3α indicating the greater role of the β isoform
in oral cancer. Among various types of oral cancers, OSCC (of the lip and tongue) showed elevated expression of
GSK3α/β, and the expression was correlated with disease progression. The increased expression of pS21GSK3α and
pS9GSK3β not only correlated positively with cyclin D1 and p53 expression in tongue cancer progression but a gradual
shift of their expression from the cytoplasmic to the nuclear compartment and overall disease severity was also
observed. The interaction of GSK3β-cyclin D1 and the positive correlation of pS9GSK3β and the transcription of cyclin
D1 were observed.
Conclusions: These results demonstrate that the inactivation of GSK3β is an important event in OSCC and can be used
as a marker for assessing disease severity and may be exploited for therapeutic intervention.Introduction
Oral cancer is the sixth most common cancer in the
world, and its incidence varies in different ecogeographic
regions [1,2]. While tobacco smoking and alcohol
consumption are major risk factors for oral cancer in
the western population, betel quid chewing with tobacco
is recognized as the predominant contributor to oral
cancer prevalence in Southeast Asia [3]. The high
incidence of oral cancer in the Jharkhand state in the
eastern part of India may be attributed to use of locally
made alcoholic beverages, such as Mohua prepared from* Correspondence: mishrark1@yahoo.co.in
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unless otherwise stated.the flowers of the mahua plant, and Hadia prepared from
fermented cereals, in addition to tobacco chewing habit.
Glycogen synthase kinase 3, a serine/threonine kinase
involved in multiple physiological processes is a highly
conserved and ubiquitously expressed member of the
CMGC family of protein kinases [4]. To date, two members
of the mammalian GSK3 family (α and β) are known.
GSK3α/β plays a major role in epithelial cell homeostasis
[5]. GSK3 proteins usually have three domains, a small
N-terminal domain, a slightly larger C-terminal domain
and a predominant middle kinase domain. In addition to
these domains, a nuclear localization sequence has also
recently been identified [6]. Its paradoxical role as a
tumor suppressor or a tumor promoter is actively under
investigation in various neoplastic diseases [7]. GSK3 is a
constitutively active enzyme in normal cells and undergoesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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upon phosphorylation at Ser21 of GSK3α and at Ser9 of
GSK3β [8]. GSK3 is a key suppressor of the canonical
Wnt signaling pathway including β-catenin [9] and
various other oncogenic transcription factors (OTFs), such
as NFκB, AP-1, c-Myc and p53, which are involved in cell
proliferation [10].
Cyclin D1, a proto-oncogene, is an important regulator
of G1 to S phase progression in many different cell types
[11]. Together with its binding partners cyclin dependent
kinase 4 and 6 (CDK4 and CDK6), cyclin D1 forms active
complexes that promote cell cycle progression [12]. Cyclin
D1 is important for the development and progression of
several cancer types, including that of oral epithelial
cancer that occurs by the transformation of the buccal
mucosa causing oral squamous cell carcinoma (OSCC)
[13]. Overexpression of cyclin D1 protein is frequently the
result of its deregulation at the post-translational level.
Active GSK3α/β phosphorylates cyclin D1, leading to its
degradation [14]; thus, suppressing signals that inactivate
GSK3α/β causes epithelial cancer [15]. Alternatively, p53
is a well-known tumor suppressor protein that is widely
reported in human cancer. Wild type p53 maintains
genomic integrity through the induction of cell cycle and
cell death regulatory genes in response to DNA damage
[16]. Although mutational inactivation of p53 has been
reported in nearly half of the oral cancer population, in
the subpopulation of OSCC cases without p53 mutations
the mechanism of p53 inactivation is still far from clear
[17]. p53 activity is regulated by active GSK3β, due to
either a physical association or phosphorylation and
post-translational modifications [18].
In the present study, an investigation was performed
to assess the expression of GSK3α/β in various stages of
oral tumor progression. The activity of GSK3α/β was also
assessed by detecting its site-specific phosphorylation in
various oral cancer samples, more elaborately in oral
tongue SCC (OTSCC) samples. The protein interaction of
GSK3α/β with cyclin D1 in various oral tumors was
determined, and the inactivation status of GSK3α/β
was correlated with the expression of pro-cell cycle
promoting cyclin D1 and with the expression of p53
in a group of random samples. The data suggest that
the inactivation of GSK3, especially GSK3β, might be
related to oral cancer progression and might fuel the
transcription of cyclin D1. These pathways may be
targeted to treat this deadly disease.
Materials and methods
Patients and tissue samples
A total of one hundred seventy-nine (n = 179) different
human oral tumors and control samples, which include
tissue microarray (TMA, OR802 and OR601a from US
Biomax) samples (n = 140) and freshly collected humanoral tumor and control samples (n = 39), were analyzed.
The fresh samples of twenty-seven oral tumor samples, six
normal samples and six PMLs samples (thick leukoplakia
n = 3; OSMF n = 3) were collected from local hospitals,
nursing homes and clinics near the Ranchi area. These
samples were collected after obtaining informed consent
from the patients, and the use of human samples was
approved by the Institutional Human Ethical Committee
of CUJ. The samples of normal and PMLs were obtained
from patients without cancer undergoing nononcologic
surgical procedures. The collected samples were divided
into two pieces and stored in liquid nitrogen and buffered
formalin. H&E sections were used to confirm the
pathologic diagnosis and the presence of lesional and
cancer tissue, verified by a pathologist. Staging of the oral
cancer samples was conducted according to American
Joint Committee on Cancer (AJCC)/International Union
against Cancer (UICC) TNM classification after brief
histological studies.
Immunohistochemistry (IHC)
IHC was performed with various oral tissue samples as
described earlier with slight modifications [19]. Briefly,
following dewaxing, washing and rehydration of the
slides through xylene and graded alcohols, microwave
heating in citrate buffer was used for antigen retrieval of
GSK3α, GSK3β and pS9GSK3β; however for pS21GSK3α
a high pH flex buffer was used. Endogenous peroxidase
was blocked in peroxidase blocking solution (DAKO).
Primary antibodies (Santa Cruz Biotechnology) p/GSK3α
(dilution 1: 15) and p/GSK3β (dilution 1: 40) were incu-
bated at 4°C overnight. The EnVision FLEX Mini Kit,
High pH (Link) (Code: K8023; DAKO) was used for
staining. The slides were then washed, and secondary
antibody (FLEX-HRP) was applied as dictated by the
manufacturer (DAKO Kit). Staining was visualized
with diaminobenzidine tetrachloride (DAB). The sec-
tions were counterstained with hematoxylin, dehy-
drated, cleared and mounted. For a negative control,
BSA was used in place of the primary antibody. A skin
cancer sample known to overexpress GSK3α/β and
pGSK3α/β protein was used as a positive control. The
normal oral mucosa samples showed moderate immuno-
reactivity to GSK3α/β and faint immunoreactivity to the
pGSK3α/β antibody. Hence, all of the immunostained
cancer samples were visualized and scored, such as 0
(no staining), 1 (least intense and staining like nor-
mal), 2 (moderately intense staining) and 3 (max-
imum intense staining) based on the staining
intensity and the extent of immunoreactivity. A score
of 0 was considered no expression and a score of 1,
2, or 3 was considered for expression of the protein
whereas a score of 2 or 3 was considered for the
overexpression of the protein.
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Western blot analysis was performed as described in detail
previously [20]. Cancerous and control tissue lysates were
prepared in RIPA buffer (20 mM Tris–HCl pH 7.5;
150 mM NaCl; 1 mM EDTA; 1 mM β-Glycerophosphate;
1% Triton X-100; 2.5 mM Sodium pyrophosphate;
1 mM Sodium orthovanadate; 1 mM PMSF; 0.5%
Sodiumdeoxycholate; 10nM Okadoic acid (freshly
prepared); 1% SDS; Protease inhibitor (freshly prepared,
1X); Phosphatase inhibitor (freshly prepared, 1X)). Protein
samples (60–100 μg) were separated using 10% SDS-PAGE
along with a ColourBurstTM Electrophoresis Marker, Sigma
(Catalog Number: C1992) and transferred to PVDF
membranes using an iBlotTM dry blotting system (BioRad).
The blots were cut according to the MW of the protein
used for WB analysis. The immunoreactivity of GSK3α was
observed much less than GSK3β and therefore a greater
amount of tissue extract (TEs) and antibody concentration
was used to detect the protein. Immunoblot analysis was
performed with the following primary antibodies (Santa
Cruz Biotechnology): pGSK3-α (Ser21): sc-101690 (100 μg
of resolved TEs, Ab dilution 1: 150); pGSK-3β (Ser9):
sc-11757(60 μg of resolved TEs, Ab dilution 1: 300);
GSK-3α (H12): sc-5264 (100 μg of resolved TEs, Ab
dilution 1: 150); GSK-3β (H-76): sc-9166 (60 μg of resolved
TEs, Ab dilution 1: 300); cyclin D1 (DCS-6): sc-20044
(60 μg of resolved TEs, Ab dilution 1: 300), p53(FL-393):
sc-6243 (60 μg of resolved TEs, Ab dilution 1: 300) and
β-actin (C4): sc-47778 (60 μg of resolved TEs, Ab
dilution 1: 1000). The following secondary antibodies
(Santa Cruz Biotechnology, dilution 1: 1500), goat
anti-rabbit IgG-HRP: sc-2004; rabbit anti-goat IgG-HRP:
sc-2768 and donkey anti-mouse IgG-HRP: sc-2314,
were used against the respective primary antibody,
and the SuperSignal(R) West Pico Chemiluminescent
Substrate (Thermo Scientific) was used to detect
horseradish peroxidase (HRP) on the immunoblots. A
developer, fixer and X-ray film (Kodak) were used to
capture the signal.
Immunoprecipitation and WB
Immunoprecipitation was performed as described
previously [21]. Tumor extracts (n = 12) of different
stages, T1/T2 (initial stage, n = 6) and T3/T4 (higher
stage, n = 6) samples, were used to determine the associ-
ation of GSK3α/β with cyclin D1. Immunoprecipitation
assays were performed using 500 μg of tumor tissue
extract (TE), 1 μg GSK3α/β antibody and Protein A/G
PLUS-Agarose Immunoprecipitation Reagent (sc-2003,
Santa Cruz Biotechnology). The samples were incubated
for two hours at RT with shaking and after thorough
washing, the immunoprecipitates were run and transferred
to PVDF membranes and processed for immunoblotting
using a cyclin D1 antibody.RT-PCR analysis
Total RNA from 28 samples (6 normal, 6 PMLs and 16
tumor samples) were isolated using the Trizol reagent.
The RNA concentration was determined from the OD at
a wavelength of 260 nm. The ratio of absorbance at
260 nm and 280 nm was calculated and RNA samples
with a ratio of 1.8 to 2.0 were considered pure and
included in the study. In total, 5 μg of isolated total
RNA was reverse-transcribed to cDNA in a reaction
mixture containing 4 μl of 5X reaction buffer, 2 μl of a
dNTPs mixture (10 mM), 20 units of an RNase inhibitor,
200 units of an avian-myeloblastosis virus (AMV)
reverse transcriptase and 0.5 μg of an oligo(dT) primer
(Promega, WI, USA) in a total volume of 20 μl. The
reaction mixture was incubated at 42°C for 60 minutes.
The reaction was terminated by heating at 70°C for
10 min, and the cDNA was used for RT-PCR. The oligos
used for RT-PCR of cyclin D1 were For: 5’ CTC CTG
TGC TGC GAA GTG GA 3’; Rev: 5’ AGA CCT CCA
GCA TCC AGG TG 3’ and GAPDH were For: 5’ATG
GCA AAT TCC ATG GCA CC3’; Rev: 5’ATC CAC
AGT CTT CTG GGT GG3’.
Statistical analysis
The immunostained tissues samples were counted, and a
score was given as described and summarized in Tables 1
and 2. Fisher’s exact test and the Chi-square test were
used to draw any conclusion. The WB experiments
were performed at least in triplicate. The bands were
densitometrically analyzed, and the arbitrary units
were used for the quantitative expression of various
proteins, such as pS21GSK3α, pS9GSK3β, cyclin D1,
and p53. The mean and SD of these arbitrary numbers
were used to plot the graphs. Student’s t-test was used to
compare the differences in various groups. Similarly, the
correlation of pS21GSK3α and pS9GSK3β expression with
cyclin D1 and p53 expression of all of the samples were
assessed via bivariate analysis using Pearson’s/Spearman’s
coefficient. In all of the experiments, a p-value <0.05 was
considered statistically significant.
Results
Protein expression of GSK3β is higher than GSK3α in
different types of oral tumors
GSK3 immunoreactivity was observed, and different
tumors showed the expression of both of the proteins
(GSK3α/β) to different extents. GSK3α/β protein
expression was observed in the cytoplasmic, nuclear and
both the cytoplasmic and nuclear regions of the cancer cells
(Figure 1). In most of the samples, intense overexpression
of GSK3β compared to GSK3α was observed. The age
group >40 ≤ 70 showed expression and overexpression
of GSK3β compared to GSK3α, and this observation
was statistically significant (p = 0.03 and p = 0.0006,






GSK3α GSK3β p-value (GSK3β over
GSK3α)
Expression Overexpression Expression Overexpression Expression Overexpression
1 Age
≤40 15 08 (53.3%) 00 (00.0%) 09 (60.0%) 03 (20.0%) NS 0.06
>40 ≤ 70 53 25 (47.1%) 05 (09.4%) 36 (67.9%) 20 (37.7%) 0.03 0.0006
>70 12 06 (50.0%) 00 (00.0%) 09 (75.0%) 07 (58.3%) NS 0.001
2 Sex
Male 49 26 (53.0%) 04 (08.1%) 33 (67.3%) 19 (38.7%) NS <0.0001
Female 31 13 (41.9%) 01 (03.2%) 20 (64.5%) 10 (32.2%) NS 0.002
3 Size
T1-T2 40 18 (45.0%) 03 (07.5%) 30 (75.0%) 23 (57.5%) 0.006 <0.0001
T3-T4 2 02 (100%) 00 (00.0%) 02 (100%) 01 (50.0%) NS NS
4 Lymph nodes
N0 42 19 (45.2%) 03 (07.1%) 28 (66.6%) 20 (47.6%) 0.04 <0.0001
N1-N3 4 02 (50.0%) 01 (25.0%) 03 (75.0%) 03 (75.0%) NS NS
5 Distant Metastasis
M0 38 19 (50.0%) 03 (07.8%) 28 (73.6%) 19 (50.0%) 0.03 <0.0001
M1 8 03 (37.5%) 01 (12.5%) 07 (87.5%) 07 (87.5%) 0.03 0.002
6 Histological grade
WDSCC 24 17 (70.8%) 02 (08.3%) 21 (87.5%) 18 (75.0%) NS <0.0001
MDSCC 7 03 (42.8%) 01 (14.2%) 07(100%) 05 (71.4%) NS NS
PDSCC 7 02 (28.5%) 01 (14.2%) 04 (57.1%) 03 (42.8%) NS NS
7 Oral cancer types
SCC 32 18 (56.2%) 03 (09.3%) 27 (84.3%) 24 (75.0%) 0.02 <0.0001
Invasive SCC 5 02 (40.0%) 01 (20.0%) 03 (60.0%) 03 (60.0%) NS NS
Mucoepidermoid carcinoma 8 04(50.0%) 01 (12.5%) 06 (75.0%) 03 (37.5%) NS NS
Adamantinoma 8 03 (37.5%) 0 (00.0%) 05 (62.5%) 01 (12.5%) NS NS
Adenoid cystic carcinoma 3 00 (00.0%) 00 (00.0%) 00 (00.0%) 00 (00.0%) N/A N/A
Basal cell carcinoma 2 00 (00.0%) 00 (00.0%) 01 (50.0%) 00 (00.0%) N/A N/A
Acinic cell carcinoma 1 00 (00.0%) 00 (00.0%) 01 (50.0%) 00 (00.0%) N/A N/A
9 Hyperplasia of Squamous
Epithelium
6 03 (50.0%) 01 (16.6%) 04 (66.6%) 01 (16.6%) NS NS
10 Cancer adjacent oral tissue 5 01 (20.0%) 00 (00.0%) 03 (60.0%) 00 (00.0%) NS NS
11 Non neoplastic oral cavity glands 11 07 (63.6%) 00 (00.0%) 06 (54.5%) 00 (00.0%) NS NS
12 Normal oral squamous epithelium 4 03 (75.0%) 00 (00.0%) 01 (25.0%) 01 (25.0%) NS NS
13 Sub-types of OSCC
Tongue 10 08 (80.0%) 01 (10.0%) 08 (80.0%) 07 (70.0%) NS 0.006
Lip 7 03 (42.8%) 00 (00.0%) 07 (100%) 07 (100%) 0.01 0.0002
Cheek 6 03 (50.0%) 00 (00.0%) 05 (83.3%) 03 (50.0%) NS 0.04
Gingiva 4 02 (50.0%) 00 (00.0%) 04 (100%) 04 (100%) NS 0.004
Others 5 02 (40.0%) 03 (60.0%) 03 (60.0%) 03 (60.0%) NS NS
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more overexpression of GSK3β compared to the
GSK3α isoform (p < 0.001). Males and females showeda greater overexpression of GSK3β compared to GSK3α
(p < 0.0001 and p = 0.002, respectively). Both expression
and overexpression of GSK3β compared to GSK3α was






pS21GSK3α pS9GSK3β p-value (pS9GSK3β over
pS21GSK3α)
Expression Overexpression Expression Overexpression Expression Overexpression
1 Age
≤40 8 04 (50.0%) 03 (37.5%) 06 (75.0%) 04 (50.0%) NS NS
>40≤ 70 42 29 (69.0%) 12 (27.9%) 37 (88.0%) 30 (71.4%) NS 0.0002
>70 07 05 (71.4%) 03 (42.8%) 06 (85.7%) 05 (71.4%) NS NS
2 Sex
Male 34 22 (64.7%) 09 (26.4%) 29 (94.5%) 22 (64.7%) NS 0.0032
Female 23 16 (69.5%) 09 (39.1%) 20 (91.3%) 17 (73.9%) NS 0.036
3 Histological grade
WDSCC 37 29 (78.3%) 17 (45.9%) 37 (100%) 32 (86.4%) 0.01 0.0004
MDSCC 06 03 (50.0%) 01 (16.6%) 06 (100%) 02 (33.3%) 0.01 NS
PDSCC 05 02 (40.0%) 00 (00.0%) 03 (60.0%) 03 (60.0%) NS NS
4 Size
T1-T2 44 31 (70.4%) 17 (36.1%) 41 (93.6%) 34 (77.2%) 0.01 0.0005
T3-T4 06 04 (66.6%) 01 (16.6%) 06 (100%) 04 (66.6%) NS NS
5 Lymph nodes
N0 47 33 (70.2%) 18 (38.2%) 44 (93.6%) 37 (78.7%) 0.006 0.005
N1-N3 03 02 (66.6%) 00 (100%) 03 (100%) 01 (33.3%) NS NS
6 Distant Metastasis
M0 50 35 (70.0%) 18 (36.0%) 47 (94.0% 38 (76.0%) 0.003 0.0001
M1 00 00 (00.0%) 00 (00.0%) 00 (00.0%) 00 (00.0%) NA NA
7 Tissue types
OSCC (Tongue) 50 35 (70.0%) 18 (36.0%) 47 (94.0% 38 (76.0%) 0.003 0.0001
Normal Tongue (Cancer adjacent) 7 03 (42.8%) 00 (00.0%) 02 (28.5%) 01 (14.2%) NS NS
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p < 0.0001). The smaller sized oral tumors showed more
expression (p = 0.006) and overexpression (p < 0.0001) of
GSK3β compared to GSK3α. Similarly, GSK3β expression
and overexpression was significantly higher than GSK3α
expression and overexpression in non-metastatic (p = 0.03
& p < 0.0001) and metastatic oral tumors (p = 0.03 &
p < 0.002), respectively. All of these independent observa-
tions demonstrate a higher expression level of GSK3β
than GSK3α in oral tumor tissue samples (Table 1).
GSK3α/β protein over-expression is significantly
associated with OSCC
Various types of oral tumors and control samples
(normal squamous epithelium, hyperplasia, cancer adjacent
oral tissue, non-neoplastic oral cavity glands, adenoid cystic
carcinoma, mucoepidermoid carcinoma, adamantinoma,
basal cell carcinoma, OSCC, and acinic cell carcinoma)
were analyzed to determine the expression of GSK3α/
β by IHC (summarized in Table 1). Normal oral mucosa,
hyperplasia and various oral cancer samples showedimmunoreactivity to both GSK3α/β antibodies to different
extents according to the extent of differentiation but some
samples did not show any reactivity. OSCC tissue
samples of the cheek (Figure 1. A (a, b)), gingiva (g, h),
lower mandible (i, j), and lip (w, x) showed a more intense
expression of GSK3β than GSK3α. Similarly, different oral
SCC (b, h, j, x) samples showed maximum immuno-
reactivity to GSK3β. The tissue samples of most of
the mucoepidermoid carcinoma showed expression of
both GSK3α and GSK3β in ductal cells (c, d and q, r and
u, v). The mandibular benign adamantinomas showed
immunoreactivity to both GSK3α and GSK3β (e, f ).
In tissue samples of adenoid cystic carcinoma, staining
was not observed, either in ductal or in myoepithelial cells
(k, l). The tissue samples of basal cell carcinoma showed
very faint expression of both GSK3α and GSK3β (m, n),
and acinic cell carcinoma showed no expression (o, p) of
either GSK3α or GSK3β. In the normal salivary gland,
staining was observed in the ductal cells only and more
expression of GSK3α than GSK3β (s, t) was observed.
Meanwhile, in total 33.75% (27/80) and 51.25% (41/80) of
Figure 1 (See legend on next page.)
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Figure 1 The expression of GSK3α and GSK3β proteins in the tumor/ normal tissues of various anatomical sites of the mouth.
(A) Representative immunostaining showing the differential expression of GSK3α and GSK3β from consecutive sections in various types of oral
tumor tissue samples as indicated in the figure. (a, b) SCC (cheek); (c, d) Mucoepidermoid carcinoma (palate); (e, f) Adamantinoma (mandible);
(g, h) SCC (gingiva); (i, j) SCC (lower mandible); (k, l) Adenoid cystic carcinoma (palate); (m, n) Basal cell carcinoma (lip); (o, p) Acinic cell carcinoma
(parotid gland); (q, r) Mucoepidermoid carcinoma (root of the tongue). (s, t) Normal salivary gland, (u, v) Mucoepidermoid carcinoma (parotid
gland) (w, x) and SCC (lip) showed differential expression of GSK3α and GSK3β. The maximum intense immunoreactivity of GSK3β was observed
in SCC compared to other types of oral tumors. Original magnification 100X. (B) Overexpression of GSK3β is significantly higher in SCC than in
the other types of (non-SCC) oral cancers (p < 0.0001).
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and GSK3α protein expression (Table 1), respectively. In
addition to OSCC, no significant correlation was observed
for various other types of oral cavity neoplasms. The
OSCC tumors of various sites, such as tongue, lip, cheek
and gingival, showed overexpression of GSK3β compared
to GSK3α and was statistically significant (at p = 0.006,
p = 0.0002, p = 0.04, p = 0.004, respectively).
The expression of GSK3α was observed more in
OSCC tumors than other types of tumors in the oral
cavity (such as mucoepidermoid carcinoma, adenoid
cystic carcinoma, basal cell carcinoma, adamantinoma,
and acinic cell carcinoma considered together) (p = 0.02).
Similarly, a significant difference was observed in theFigure 2 The expression of active/inactive GSK3β proteins in various
representative photomicrograph shows GSK3β expression in the (a) nuclea
normal tongue (200X). (c) GSK3β expression in the nuclear and cytoplasmic
expression in the (a) cytoplasmic compartment in a MDSCC of an OTSCC s
sample. (C) A graph showing the percentage of samples of an initial grade
and the shifting of pS9GSK3β from the cytoplasm to the nucleus trend in toverexpression of GSK3β in OSCC tumors compared with
other types of tumors as indicated in Table 1 (p < 0.0001;
Figure 1B). These results clearly demonstrate a greater
role of GSK3β overexpression (which was later found to
be mostly inactive) in OSCC.
The cellular expression and distribution of GSK3 was
located within different cellular compartments. GSK3β
expression was observed in eleven higher grade (MDSCC
and PDSCC) tumors. It was expressed in the nuclear
compartment (NC), the nuclear-cytoplasmic compartments
(N-CC) (Figure 2A (c)) and in only the cytoplasmic
compartment (CC) in 5, 4 and 2 cases, respectively.
Alternatively, in the lower grade tumors (WDSCC), 4, 5
and 12 samples were found to have positive expression ofcellular compartments in normal/OTSCC tissues samples. (A) The
r compartment (NC) and (b) cytoplasmic compartment (CC) of a
compartments (N-CC) in a WDSCC of OTSCC (100X). (B) pS9GSK3β
ample and (b) the nuclear compartment in a PDSCC of an OTSCC
(grade-1) or a higher grade (grade 2–3) showing pS9GSK3β expression
he higher grade samples (p = 0.01).
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GSK3β expression shifting from the cytoplasmic to the
nuclear compartment according to disease severity was
observed (p = 0.09, though was not significant due to
sample size). Alternatively, among the five (5/14) positive
tumors of a higher grade (MDSCC and PDSCC), the
expression of GSK3α was observed in the NC, N-CC and
CC in 2, 2 and 1 of the tumor samples, respectively.
Likewise, in the lower grade tumor (WDSCC) samples,
GSK3α expression was observed in various cellular
compartments, including 5 samples that express it in only
the NC, 3 samples in the N-CC and 9 samples in the CC.Figure 3 The expression of GSK3α/β proteins at various stages of OSCC
differential expression of GSK3α and GSK3β from consecutive sections of lip S
lip and (e, f) SCC of the lip. (B) Representative immunostaining showing the d
OTSCC tissue progression, including (a, b) normal tongue; (c, d) hyperplasia o
distant metastasis of SCC cells at the lymph nodes from various OSCC showin
in the consecutive sections (a to h). The metastatic OTSCC showed maximumThe normal samples showed expression of GSK3β in the
NC and CC in one sample (Figure 2A (a, b)) and the
expression of GSK3α in the NC and CC in two and one of
the samples, respectively.
GSK3α and GSK3β protein expression pattern in the
progression of OSCC
Statistics were gathered to determine the expression of
GSK3α and GSK3β in OSCC progression. The results
showed that in the normal lip, no immunoreactivity was
observed for both the GSK3α and the GSK3β antibody
(Figure 3A (a, b)). However, in the normal tongue tissue,progression. (A) Representative immunostaining showing the
CC tissue progression, including (a, b) normal lip, (c, d) hyperplasia of the
ifferential expression of GSK3α and GSK3β from consecutive sections of
f the tongue and (e, f) SCC of the tongue. (C) Photomicrographs showing
g immunoreactivity to GSK3α and GSK3β antibodies to different extents
expression of GSK3β (original magnification 100X).
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the peripheral epithelial layer in most of the cases (Figure 3B
(a, b)), except one sample that showed strong immunoreac-
tivity to the GSK3β antibody. In the tissue samples with
mild hyperplasia, the expression of GSK3α and GSK3β was
observed, and it was limited to the deeper epithelial zone of
both the lip and tongue tissues (Figure 3A (c, d) & B (c, d)).
Alternatively, the expression of the GSK3α/β protein was
observed in the tumors of the lip and tongue (Figure 3A
(e, f) & B (e, f)). In the OTSCC progression model, a total
of twenty-two samples were analyzed, and GSK3β overex-
pression was observed in 14.2% (1/7) of normal samples, in
20.0% (1/5) of hyperplasia and 70.0% (7/10) of cancer
samples (p = 0.0396). In the lip cancer progression
model, a total of fifteen samples were analyzed and GSK3β
overexpression was not observed in normal (n = 2) or
hyperplasia (n = 3) samples but was observed in 70.0%
(7/10) of cancer samples (p = 0.0376). In the distant
metastatic SCC samples, the invasive cancer cells at
the new location demonstrated an overexpression of
GSK3β in 87.5% (7/8) whereas only 12.5% (1/8) of samples
showed an overexpression of GSK3α (p = 0.002) (Table 1
and Figure 3C (a to h)). Similarly, nearby lymph node
positive cases were found in 60% (3/5) of the GSK3β
overexpressing tumors and in only 20% (1/5) of the
GSK3α overexpressing tumors.Figure 4 The inactivation of GSK3 proteins at various stages of OTSC
differential expression of pS21GSK3α and pS9GSK3β in the consecutive sect
adjacent tongue, and (e, f) OTSCC tissue samples (original magnification 10Progressive inactivation of the GSK3α/β protein
expression in the OTSCC
Inactivation of the GSK3 proteins was detected by
determining the expression of pS21GSK3α and pS9GSK3β
at various stages in OTSCC progression. Cancer adjacent
apparently normal tongue samples showed faint immuno-
reactivity of pS21GSK3α and pS9GSK3β in 42.8% (3/7) and
28.5% (2/7) of the samples (Figure 4. a, b), respectively.
However, the overexpression of pS9GSK3β was not
observed in 85.7% (6/7) of cancer adjacent normal looking
tongue samples. One tumor adjacent tongue sample with
mild hyperplasia showed moderate expression of both
pS21GSK3α and pS9GSK3β (Figure 4. c, d). Alternatively,
in total 85.96% (49/57) and 66.6% (38/57) of OTSCC
tissue samples showed pS9GSK3β and pS21GSK3α protein
expression, respectively (Figure 4 e, f ) (Table 2). Moreover,
80% (8/10) of the OTSCC samples showed immunoreac-
tivity to GSK3α and GSK3β antibodies (Table 1). If this
statistic remains consistent, then all of the OTSCC
samples that express GSK3β may be inactivated and
nearly 15.0% of all of the OTSCC samples that express
GSK3α may still remain active.
Both male and female patient tissue samples showed
overexpression of pS21GSK3α (p = 0.0032) and pS9GSK3β
(p = 0.036). Meanwhile, in the age group >40 ≤ 70, the
over-expression of inactive GSK3β compared to GSK3αC progression. Representative immunostaining showing the
ions of (a, b) normal tongue tissue, (c, d) mild hyperplasia of tumor
0X).
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GSK3β expression was observed more than GSK3α expres-
sion in small sized (T1-T2 group) tumors (p = 0.0005). The
over-expression of the pS9GSK3β protein was observed in
86.4% of WDSCC (32/37), 33.3% of MDSCC (2/6) and
60.0% of PDSCC (3/5) samples (p = 0.01). Alternatively, the
expression of the pS9GSK3β protein was observed in all of
the WDSCC and MDSCC (43/43) and observed in at
least 60.0% of the PDSCC (3/5) samples (p = 0.0001).
Nuclear accumulation of pGSK3α/β protein expression in
the OTSCC
The distribution of pS9GSK3β was observed in the
nuclear, cytoplasmic or both cellular compartments in
human OTSCC samples (Figure 2B (a, b)). Among the nine
pS9GSK3β-expressing tumors of a higher grade (MDSCC
and PDSCC), pS9GSK3β expression was observed in
the NC, N-CC and in only CC in 6, 2 and 1 samples,
respectively. Alternatively, in the lower grade tumors
(WDSCC), 8, 6 and 23 samples showed pS9GSK3β
expression in the NC, N-CC and in only CC, respectively
(Figure 2B (a, b)). This trend of pS9GSK3β expression
shifting from the cytoplasmic to the nuclear compartment
with tumor progression was significant (p = 0.01; Figure 2C).Table 3 Patient characteristics and expression of pS21GSK3α,
tissue samples
























Not Positive 16 0Alternatively, a faint reactivity of pS21GSK3α was observed
in the OTSCC samples. Among the pS21GSK3α-stained five
positive tumors of a higher grade (MDSCC and PDSCC),
the expression in the NC, N-CC and only CC was observed
in 3, 1 and 1 tumor samples, respectively. Similarly, in the
lower grade tumors (i.e., WDSCC), 4, 7 and 18 tumor
samples were positive for pS21GSK3α in the NC, N-CC and
in only CC, respectively (p = 0.054).
Inactivation of GSK3α/β and their correlation with cyclin
D1 and p53 in human OSCC
The expression of GSK3α/β, cyclin D1 and p53 (n = 39;
Table 3) was detected using WB analysis. Detectable
expression of GSK3α was observed in 83.3% normal (5/6),
66.6% PMLs (4/6), and 51.8% tumor samples (14/27).
Similarly, the expression of GSK3β was observed in 83.3%
normal (5/6), 83.3% PMLs (5/6) and 59.25% oral tumor
(16/27) samples. Moreover, 25.9% (7/27) and 40.7% (11/27)
of oral tumor samples showed decreased expression of
GSK3α and GSK3β expression compared to normal sam-
ples. The expression of pSer21GSK3α and pSer9GSK3β was
not observed in normal samples and less expression was
observed in the PMLs samples. Alternatively, 81.4% (22/27)
and 85.1% (23/27) of the OSCC samples showedpS9GSK3β, cyclin D1 and P53 in oral cancer and control
amples showing the positive expression of proteins (n)
yclin D1 P53 pS21GSK3α pS9GSK3β
7 (73.9%) 08 (34.7%) 12 (52.1%) 14 (60.8%)
8 (50.0%) 08 (50.0%) 10 (62.5%) 09 (56.2%)
4 (60.8%) 10 (43.4%) 13 (56.5%) 14 (60.8%)
1 (68.7%) 06 (37.5%) 09 (56.2%) 09 (56.2%)
0 (00.0%) 01 (16.6%) 00 (00.0%) 00 (00.0%)
6 (100%) 03 (50.0%) 01 (16.6%) 02 (33.3%)
0 (66.6%) 07 (46.6%) 10 (66.6%) 11 (73.3%)
6 (100%) 05 (83.3%) 06 (100%) 05 (83.3%)
3 (50.0%) 01 (16.6%) 05 (83.3%) 05 (83.3%)
4 (60.8%) 11 (47.8%) 12 (52.1%) 13 (56.5%)
1 (68.7%) 05 (31.2%) 10 (62.5%) 10 (62.5%)
8 (81.8%) 12 (54.5%) 22 (100%) 20 (90.9%)
7 (41.1%) 04 (23.5%) 00 (00.0%) 03 (17.6%)
8 (78.2%) 11 (47.8%) 20 (86.9%) 23 (100%)
7 (43.7%) 05 (31.2%) 02 (12.5%) 00 (00.0%)
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spectively. Overexpression of the cyclin D1 protein was ob-
served in 70.3% (19/ 27) of OSCC samples and in 100% (6/
6) of PMLs compared to the normal oral mucosa tis-
sue samples. Expression of the p53 protein was ob-
served in 48.1% (13/ 27) of the OSCC samples, 50.0%
(3/6) of the PMLs samples and 16.6% (1/6) of the
normal oral mucosa samples. β-Actin was used as a
loading control in these experiments (Figure 5A).
The expression of pS9GSK3β (p = 0.001) and pS21GSK3α
(p = 0.0001) was significantly different in tumors compared to
normal and PMLs (Figure 5B (a and b)). Similarly, cyclin D1
protein expression was observed more in tumor samples and
PML samples than in normal samples (p = 0.0001; Figure 5B
(c)). The overexpression of the p53 protein was greater in oral
tumor samples than in the normal counterpart (p = 0.0001;
Figure 5B (d)). Further, the expression of pS21GSK3α and
pS9GSK3βwas positively correlated with cyclin D1 expression
(p = 0.0001 and p = 0.002, respectively; Figure 5C (a, b)).
Similarly, p53 expression was positively correlated with
the expression of pS21GSK3α and pS9GSK3β (p = 0.01 and
p = 0.001, respectively; Figure 5C (c, d)).
The interaction of GSK3α/β with cyclin D1 in human OSCC
The interaction of GSK3β and cyclin D1 was observed in
various oral tumor samples (Figure 6A). Alternatively, a
GSK3α-cyclin D1 interaction was not observed. A GSK3β-
cyclinD1 associationwas observed in 100% (6/6) of the higher
stage (T3/T4) tumors compared to 66.6% (4/6) of the initial
stage (T1/T2) oral tumors samples. The expression of
pS9GSK3β, total GSK3β and cyclin D1 was detected in the
corresponding WCE (Figure 6B) and was correlated with the
extent of the GSK3β-cyclin D1 interaction. The results show
no statistically significant correlation between the extent of
the GSK3β-cyclin D1 interaction and the level of expression
of total GSK3β, pS9GSK3β, and cyclin D1. Moreover, no cor-
relation was observed between the extent of the interaction
and the active fraction of GSK3β (arbitrary units of theGSK3β
readingminus the pS9GSK3β reading) as shown in Figure 6C.
Correlation of GSK3α/β inactivation status with cyclin D1
transcription in human OSCC
RT-PCR analysis was performed to determine the
expression of cyclin D1 mRNA in various tumor, PML
and normal samples (Figure 7A). PMLs and tumor
samples showed increased cyclin D1 mRNA levels
compared to normal oral mucosa (Figure 7B). The mRNA
expression was correlated with the protein expression in
the same tissue samples. The correlation of pS21GSK3α
expression with cyclin D1 mRNA expression was not
significant (n = 28, Pearson’s r = 0.2896, p = 0.135) whereas
the correlation of pS9GSK3β expression with cyclin
D1 mRNA expression was significant (n = 28, Pearson’s
r = 0.8624, p < 0.0001; Figure 7C and D).Discussion
The deregulation of GSK3 is involved in several types of
human cancer and neurodegenerative diseases [7,22]. It
has two isoforms, GSK3α and GSK3β, and their expression
varies in different tissue types [23]. To the best of our know-
ledge, no reports are available regarding the variation of both
isoforms (GSK3α and GSK3β) in human mouth cancer. The
present study revealed an increased protein expression of
GSK3β compared to GSK3α in various types of mouth neo-
plasms. Although the overexpression of GSK3β and the mild
expression of GSK3α were found in various types of can-
cer and benign tumors of the mouth, the expression
was mainly detected in OSCC. Mucoepidermoid car-
cinoma and normal salivary glands exhibited expres-
sion of GSK3α and GSK3β, mainly in the ductal cells.
The expression of total GSK3α/β in the tumor sam-
ples generally increased from the normal expression
level but a small fraction of the tumor tissue also
showed the opposite trend. Previously, GSK3β expres-
sion has been correlated with a favorable outcome in
OTSCC [24]. We also observed very high overexpression
of GSK3β in the tongue tissue samples of normal, benign,
malignant and even metastatic cancers. There have been a
number of conflicting reports concerning the extent of
tumor progression and the expression of total GSK3β in
human cancers [25,26]. In the present study, we found
that GSK3β expression plays a key role in oral cancer. The
cause may be that the major pool of total GSK3 is inacti-
vated, which was consistent with our earlier report on
DMBA-induced hamster cheek pouch carcinomas [19].
The site-specific phosphorylation of pS21GSK3α and
pS9GSK3β residues changes their activity and makes them
catalytically inactive [10]. Because we have observed more
GSK3s in the tongue samples, its inactivation status was also
detected. The expression level of pS21GSK3α and pS9GSK3β
steadily increased from normal to hyperplasia to benign tu-
mors to carcinomas, indicating that there is an active role of
inactive GSK3α/β in OTSCC progression. The inactivation
of GSK3β was reported in tongue cancer [27,28]. To the
best of our knowledge, this is the first report showing
the inactivation of GSK3α in OTSCC. Our present
study provides evidence that the progressive inactivation
of GSK3α/β is a common event in human OTSCC.
The experimental results provide evidence of a decrease in
GSK3α/β levels in some OSCC tumors compared to normal.
This observation may be due to IHC staining, either by over
fixation of the tissue samples or silencing of GSK3α/GSK3β.
The latter seems to be true because some of the fresh tissue
samples showed decreased reactivity to the GSK3α/β anti-
body. This result may be due to the deregulation of tran-
scription, reduced mRNA stability or rapid protein
turnover. Further investigation is warranted to investigate
the mechanism of down regulation of GSK3α/β in certain
fractions of oral cancer. There seems to be alternative
Figure 5 WB analysis to show the expression of in/active GSK3, cyclin D1 and p53 proteins at various stages of OSCC. (A) Representative
blot showing the expression of GSK3α, GSK3β, pSer21GSK3α, pSer9GSK3β, cyclin D1 and p53 in various normal, PMLs and OSCC samples. β-Actin was
used as a loading control in this experiment. (B) The mean and SD of each protein band has been plotted for the normal, PML and OSCC samples.
Statistical analysis was performed using Student’s t-test. Statistical significance was observed among various groups: **p = 0.001, ***p < 0.0001 as
indicated in the figure. The comparison of (a) pS9GSK3β, (b) pSer21GSK3α, (c) cyclin D1, and (d) p53 protein expression among the groups of samples.
(C) A positive correlation was obtained in different pairs: (a) pSer9GSK3β and cyclin D1 (p = 0.002), (b) pSer21GSK3α and cyclin D1 (p = 0.001), (c)
pSer21GSK3α and p53 (p = 0.0001), and (d) pSer9GSK3β and p53 (p = 0.01).
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Figure 6 The interaction of GSK3β with cyclin D1 in different stages oral cancer progression. (A) The interaction of GSK3β with cyclin D1
in various oral tumor extracts (T1-T2 TE lane 3–5 & 11–13 and T3-T4 TE in lane 6–8 and 14–16). The input IgG and IgG adsorbed in TEs served as
controls. (B) The expression levels of GSK3β, pSer9GSK3β, cyclin D1 and β-actin in the TEs were checked in the TEs used for interaction studies.
(C) No significant correlation was observed in the interaction of GSK3β-cyclin D1 with the expression of various proteins as indicated.
Figure 7 The correlation of pSer21GSK3α/pSer9GSK3β expression with cyclin D1 transcription in various OSCC samples. (A) RT-PCR
showing cyclin D1 mRNA expression (201 bp PCR product) in different normals (lane 1–3), PMLs (lane 4–6) and oral cancer samples of various
stages (T1-T2 samples lane 7–10; T3-T4 samples lane 11–15). GAPDH expression (410 bp PCR product) was used as a control in this experiment.
(B) A histogram showing the level of expression of cyclin D1 mRNA in various groups (N-Normal, PML, T-Tumor) of samples as indicated. No significant
correlation (C) of cyclin D1 mRNA expression and pSer21GSK3α protein expression was observed, and a positive correlation (D) between cyclin D1
mRNA expression and the expression of pSer9GSK3β was observed.
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Mishra et al. Molecular Cancer  (2015) 14:20 Page 14 of 16mechanisms that inactivate GSK3α/β, leading to silencing,
to promote OSCC.
The protein expression of GSK3α/β and phospho-
GSK3α/β was detected in different cellular compartments
(such as NC, N-CC and CC). A higher expression of
pS9GSK3β was observed in the nuclear compartments in
the higher grade OTSCC (p = 0.01). Though the correlation
of the expression of p21GSK3α with higher grade samples
was not statistically significant, a similar trend was
observed. Alternatively, in OTSCC, cytoplasmic expression
of pS9GSK3β and p21GSK3α was associated with low grade
histology. Hence, the pGSK3α/β protein accumulates and/
or translocates from the cytoplasm to the nucleus to a
greater extent as OTSCC progresses. With regard to the
tumor adjacent (apparently normal) tissues and hyperplasia
that displayed no staining or faint staining of pS9GSK3β
and pS21GSK3α in the cytoplasmic regions, it seems that in-
active GSK3α/β expression in the cytoplasm contributes toFigure 8 A proposed model for defining GSK3-mediated deregulation
and regulatory molecules contribute to the loss of function of GSK3 by rev
GSK3 may shift to various cellular compartments, fuel cyclin D1 transcriptio
silent, due to degrading cyclin D1 or activating p53, to transform the oral mtumor progression whereas nuclear expression of inactive
GSK3α/β leads to a more severe disease. This finding may
have predictive value for OTSCC and its outcome.
Cyclin D1 has been established as a potent proto
oncogene, and the overexpression of cyclin D1 has been
observed frequently in human cancer, including OSCC
[29]. Cyclin D1 turnover is dependent on threonine286
phosphorylation, and active GSK3β was also shown to
promote this event [14]. In this context, the positive
correlation of inactive GSK3α/β with cyclin D1 is encour-
aging. The robust interaction of GSK3β with cyclin D1 was
observed in oral tumor samples. We were unable to detect
whether the active or inactive fraction of GSK3β interacted
with cyclin D1 due to technical difficulties (antibody heavy
chain interferences). Surprisingly, the advanced stage
tumors showed a greater interaction of GSK3β with
cyclin D1, which was counterintuitive to our finding of
progressive inactivation of GSK3β. Moreover, a significantof cell division in oral cancer. Diverse upstream signaling pathways
ersible phosphorylation, inactivating GSK3. These functionally altered
n possibly by increasing the activity of various TFs or may remain
ucosa leading to OSCC.
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and cyclin D1 mRNA expression was compared. This
observation may be due to the activation of some down-
stream TFs of GSK3β to fuel cyclin D1 expression and
boost the uncontrolled cell division program in OSCC.
p53 is the guardian of the genome and a well-known
tumor suppressor, and its loss of function is the most
frequent genetic event in human cancer [30,31]. Although
it is inactivated by a number of pathways, GSK3β is a key
regulatory molecule of p53 [32]. GSK3 has been reported
to phosphorylate p53 on Ser33-p53 or Ser315-p53 and
Ser376-p53 and promote the acetylation of p53, thus
controlling the function of p53 [18]. There are numerous
studies on p53 expression in OSCC that are inconclusive
[33]. However, the results of the present study indicate
that p53 expression is higher in the subset of oral tumors
with inactive GSK3. A positive correlation was observed
between inactive GSK3 and p53 expression. Inactive
GSK3 as a result of number of major signaling pathways
including the phosphatidyl-inositol-3-kinase (PI3K) path-
way, the Wnt pathway, Hedgehog signaling and Notch sig-
naling, may modulate the status of many oncogenic TFs,
RNA-binding proteins, miRNAs, and might be the cause of
increased p53 expression in OSCC [34-36]. The exact
molecular mechanism of GSK3β mediated p53 expression
remains unexplored. Moreover, in parallel with the oral
tumor progression, the nuclear accumulation of pS9GSK3β
was observed, and this observation may be an impediment
to activate p53 and may restrict uncontrolled cell division.
Finally, growth factor stimulation and oncogenic trans-
formation may lead to increased glucose metabolism in the
transformed oral mucosa that may increase the pool of
inactive GSK3. This inactive GSK3 (mainly GSK3β) may
initiate a signaling mechanism that promotes transcrip-
tional activation of cyclin D1 by targeting some yet
unknown TFs to fuel OSCC. Moreover, the inhibition of
kinase activity and the shift in cellular compartments may
affect the subpopulation of p53 that is not inactivated by a
mutation (Figure 8). Our study strongly suggests that GSK3
expression may be used as a molecular marker for
the diagnosis and therapeutic intervention of OSCC.Conclusion
In summary, although increased expression of both
GSK3α and GSK3β was associated with human oral
tumor pathogenesis, progressive inactivation of GSK3β
was observed in OSCC particularly in OTSCC. A positive
correlation was observed between expression of pS9GSK3β
and cyclin D1 protein expression, p53 protein expression
and cyclin D1 mRNA expression in human oral cancer/
control tissue samples. Hence, the expression of pS9GSK3β
can be used as a marker for assessing disease severity.
Further research is warranted to elucidate the additionalmechanisms involved so as to develop appropriate
therapeutic interventions.
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